Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.85 -0.15 (-0.54%)

Streaming Delayed Price Updated: 11:47 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies ↗

September 23, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. ...

Via Benzinga

Beam Therapeutics's Return On Capital Employed Insights ↗

September 22, 2021

According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company...

Via Benzinga

Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial ↗

September 15, 2021

The FDA has signed off Magenta Therapeutics Inc's (NASDAQ: MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA...

Via Benzinga

Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy? ↗

September 12, 2021

One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.

Via The Motley Fool

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗

September 03, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Via InvestorPlace

The 3 Best Biotech Stocks to Buy Right Now ↗

August 27, 2021

Let your portfolio reflect your personality.

Via The Motley Fool

3 Stocks to Avoid if Cathie Wood's ARK ETF Falls ↗

August 21, 2021

They likely to do the worst if Michael Burry is right.

Via The Motley Fool

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗

July 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Via The Motley Fool

WHO Issues Framework For Governance For Gene Editing Technologies ↗

July 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

Via Benzinga

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

Via Talk Markets

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

Is It Too Late to Buy Intellia Therapeutics? ↗

July 10, 2021

After skyrocketing 68% last week, will this stock keep running higher?

Via The Motley Fool

Why Beam Therapeutics Climbed 64.5% in June ↗

July 08, 2021

A gene editing milestone sent the entire sector higher last month.

Via The Motley Fool

61 Biggest Movers From Yesterday ↗

July 07, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday....

Via Benzinga

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures ↗

July 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc...

Via Benzinga

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗

July 01, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...

Via Benzinga

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

Why Gene Editing Stocks Are Trading Higher Again Today ↗

June 30, 2021

Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA

Via Benzinga

72 Biggest Movers From Yesterday ↗

July 01, 2021

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...

Via Benzinga

Topics Initial Public Offering

Why Beam Therapeutics Jumped Today ↗

June 28, 2021

A first for CRISPR-Cas9 might signal a new phase in the gene-editing revolution.

Via The Motley Fool

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR ↗

June 28, 2021

Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion....

Via Benzinga

24 Stocks Moving in Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...

Via Benzinga

2 Winners for a Drug Development Future That Looks Nothing Like the Past ↗

June 04, 2021

A new breed of disruptors is delivering breakthroughs in genomics.

Via The Motley Fool

Cathie Wood's Ark Loads Up Further On Tesla And Cuts Apple Stake ↗

May 19, 2021

Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: TSLA) after a two-week gap during which shares of the...

Via Benzinga

Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day ↗

May 14, 2021

Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.